Drug Profile
Research programme: acromegaly therapeutics - Ipsen Bioinnovation
Alternative Names: SXN 101959Latest Information Update: 22 Feb 2023
Price :
$50
*
At a glance
- Originator Syntaxin
- Developer Ipsen Bioinnovation
- Class Bacterial toxins; Botulinum toxins; Recombinant proteins
- Mechanism of Action Growth hormone releasing factor agonists; Pituitary hormone inhibitors; SNARE protein antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acromegaly
Most Recent Events
- 22 Feb 2023 Discontinued - Preclinical for Acromegaly in United Kingdom (Parenteral)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Acromegaly in United Kingdom (Parenteral)
- 24 Jul 2013 SXN 101959 is still in preclinical development for Acromegaly in the United Kingdom